Kenji Nakamaru

880 total citations
23 papers, 512 citations indexed

About

Kenji Nakamaru is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Kenji Nakamaru has authored 23 papers receiving a total of 512 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 8 papers in Pulmonary and Respiratory Medicine and 7 papers in Molecular Biology. Recurrent topics in Kenji Nakamaru's work include HER2/EGFR in Cancer Research (9 papers), Lung Cancer Treatments and Mutations (7 papers) and Cancer-related Molecular Pathways (4 papers). Kenji Nakamaru is often cited by papers focused on HER2/EGFR in Cancer Research (9 papers), Lung Cancer Treatments and Mutations (7 papers) and Cancer-related Molecular Pathways (4 papers). Kenji Nakamaru collaborates with scholars based in Japan, United States and Germany. Kenji Nakamaru's co-authors include Masanori Asakura, Tadashi Isomura, Masafumi Kitakaze, Hidehiko Furukawa, Hitonobu Tomoike, María C. Garrido, Thomas Botton, Timothy H. McCalmont, A. Hunter Shain and Takeshi Isoyama and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and Blood.

In The Last Decade

Kenji Nakamaru

23 papers receiving 500 citations

Peers

Countries citing papers authored by Kenji Nakamaru

Since Specialization

Citations

This map shows the geographic impact of Kenji Nakamaru's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kenji Nakamaru with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kenji Nakamaru more than expected).

Fields of papers citing papers by Kenji Nakamaru

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kenji Nakamaru. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kenji Nakamaru. The network helps show where Kenji Nakamaru may publish in the future.

Co-authorship network of co-authors of Kenji Nakamaru

This figure shows the co-authorship network connecting the top 25 collaborators of Kenji Nakamaru. A scholar is included among the top collaborators of Kenji Nakamaru based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kenji Nakamaru. Kenji Nakamaru is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The Tumor Immune Microenvironment and Therapeutic Efficacy of Trastuzumab Deruxtecan in Gastric Cancer 2024 ·Cancer Research Communications ·(unknown), Shohei Koyama, Fumitaka Suto, (unknown), (unknown), (unknown), Takeo Arita, (unknown), Hiroki Goto, Naoya Wada, Maki Kobayashi, Tomoko Shibutani, (unknown), Kenji Nakamaru, Akihito Kawazoe, Yosuke Togashi, Hiroyoshi Nishikawa, Kohei Shitara	1
2	Abstract 4891: Ifinatamab deruxtecan (I-DXd), a novel B7-H3-targeting antibody-drug conjugate, demonstrates efficient payload delivery into tumor through target-dependent internalization 2023 ·Cancer Research ·(unknown), Tsuneo Deguchi, Jun Hasegawa, (unknown), Yumi Nishiya, Akiko Watanabe, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Gernot Polier, Xuya Wang, Takanori Yoshida, Nanae Izumi, Xiaozhong Qian, Toshinori Agatsuma, Kenji Nakamaru	2
3	Patritumab deruxtecan (HER3-DXd), a novel HER3 directed antibody drug conjugate, exhibits in vitro activity against breast cancer cells expressing HER3 mutations with and without HER2 overexpression 2022 ·PLoS ONE ·Kumiko Koyama, H Ishikawa, Manabu Abe, Yoshinobu Shiose, (unknown), Yang Qiu, Kenji Nakamaru, Masato Murakami	20
4	Abstract 5376: Pleclinical investigation of T-DXd internalization and payload release in HER2 mutant non-small cell lung cancer cells 2022 ·Cancer Research ·A. Yamasaki, (unknown), Manabu Abe, Tsuneo Deguchi, Yasuki Kamai, Kenji Nakamaru, Toshinori Agatsuma	2
5	Abstract 5201: U3-1402, a novel HER3-targeting antibody-drug conjugate, exhibits in vitro antitumor activity against breast cancer cells expressing HER3 mutations without dependence on HER2 overexpression 2020 ·Cancer Research ·Kumiko Koyama, H Ishikawa, Manabu Abe, Yoshinobu Shiose, (unknown), Kenji Nakamaru, Masato Murakami	1
6	Predictive Gene Signatures Determine Tumor Sensitivity to MDM2 Inhibition 2018 ·Cancer Research ·Jo Ishizawa, Kenji Nakamaru, Takahiko Seki, (unknown), Kensuke Kojima, Dhruv Chachad, Ran Zhao, Lauren Heese, Wencai Ma, Man Chun John, Courtney D. DiNardo, Sherry Pierce, Keyur P. Patel, Archie Tse, R. Eric Davis, Arvind Rao, Michael Andreeff	44
7	Safety and pharmacokinetics of DS-6051b in Japanese patients with non-small cell lung cancer harboring ROS1 fusions: a phase I study 2018 ·Oncotarget ·Yutaka Fujiwara, Masayuki Takeda, Noboru Yamamoto, Kazuhiko Nakagawa, Kaname Nosaki, Ryo Toyozawa, (unknown), Ryota Shiga, Kenji Nakamaru, Takashi Seto	34
8	Development of a Novel Next-Generation Sequencing (NGS)-Based Assay for Measurable Residual Disease (MRD) in FLT3-ITD AML and Its Potential Clinical Application in Patients Treated with Chemotherapy Plus FLT3 Inhibitors 2018 ·Blood ·Mark J. Levis, (unknown), Ken C. N. Chang, Christian Laing, Flora Berisha, Emily Adams, Christopher D. Gocke, Wei Ding, Kenji Nakamaru, Jelveh Lameh, Reinhold Pollner, Ken Kobayashi	2
9	Abstract 1586: Evaluation of AXL expression on circulating tumor cells from EGFR mutated lung cancer patients who have relapsed after the EGFR TKI treatment 2018 ·Cancer Research ·(unknown), Myoung Shin Kim, (unknown), Hyun Kyung Lee, Jae Hyuk Lee, (unknown), (unknown), Kenji Nakamaru, Kenichi Wakita, (unknown), (unknown), Se‐Hoon Lee	1
10	First-in-human study of DS-6051b in patients (pts) with advanced solid tumors (AST) conducted in the US. 2018 ·Journal of Clinical Oncology ·Kyriakos P. Papadopoulos, Leena Gandhi, Pasi A. Jänne, Sai‐Hong Ignatius Ou, Alice T. Shaw, Terri Goldberg, Jonathan Greenberg, Xuemin Gu, Masaya Tachibana, Giorgio Senaldi, Ryota Shiga, Hamim Zahir, Kenji Nakamaru, Erkut Borazanci	15
11	P2.06-002 Phase I Study of DS-6051b, a ROS1/NTRK Inhibitor, in Japanese Subjects with Advanced Solid Tumors Harboring Either a ROS1 or NTRK Fusion Gene 2017 ·Journal of Thoracic Oncology ·Kaname Nosaki, Yutaka Fujiwara, Masayuki Takeda, Noboru Yamamoto, Kazuhiko Nakagawa, (unknown), Ryota Shiga, Kenji Nakamaru, Takashi Seto	4
12	Real-Time Reverse-Transcription Quantitative Polymerase Chain Reaction Assay Is a Feasible Method for the Relative Quantification of Heregulin Expression in Non–Small Cell Lung Cancer Tissue 2017 ·Biomarker Insights ·(unknown), (unknown), Xiaoping Jin, Kenji Nakamaru, Matthias Schneider, Robert A. Beckman, Daniel J. Freeman, (unknown), Wenqin Feng	4
13	Discovery of Predictive Gene Signatures for Tumor Sensitivity to MDM2 Inhibition in Development of a Novel MDM2 Inhibitor DS-3032b 2016 ·Blood ·Jo Ishizawa, Kenji Nakamaru, Takahiko Seki, (unknown), Kensuke Kojima, Dhruv Chachad, Courtney D. DiNardo, Sherry Pierce, Keyur P. Patel, Archie Tse, R. Eric Davis, Arvind Rao, Michael Andreeff	1
14	Clinical Translation and Validation of a Predictive Biomarker for Patritumab, an Anti-human Epidermal Growth Factor Receptor 3 (HER3) Monoclonal Antibody, in Patients With Advanced Non-small Cell Lung Cancer 2015 ·EBioMedicine ·Jeanne Mendell, Daniel J. Freeman, Wenqin Feng, Thore Hettmann, Matthias Schneider, Sabine Blum, Jens E. Ruhe, Johannes Bange, Kenji Nakamaru, Shuquan Chen, Zenta Tsuchihashi, Joachim von Pawel, Catherine Copigneaux, Robert A. Beckman	30
15	Abstract B5: Preclinical characterization of a novel orally-available MDM2 inhibitor DS-3032b: Anti-tumor profile and predictive biomarkers for sensitivity 2015 ·Molecular Cancer Therapeutics ·Kenji Nakamaru, Takahiko Seki, (unknown), Archie Tse	10
16	Activation of Ecto-5′-Nucleotidase in the Blood and Hearts of Patients With Chronic Heart Failure 2008 ·Journal of Cardiac Failure ·Masashi Fujita, Masanori Asakura, Shoji Sanada, Hiroharu Funaya, Osamu Tsukamoto, Kazuo Komamura, Hiroshi Asanuma, Satoshi Taketani, Tadashi Isomura, Kenji Nakamaru, Hidehiko Furukawa, Yoshiki Sawa, Masatsugu Hori, Masafumi Kitakaze	7
17	Impact of Adenosine Receptor Signaling and Metabolism on Pathophysiology in Patients with Chronic Heart Failure 2007 ·Hypertension Research ·Masanori Asakura, Hiroshi Asanuma, Jiyoong Kim, Yulin Liao, Kenji Nakamaru, Masashi Fujita, Kazuo Komamura, Tadashi Isomura, Hidehiko Furukawa, Hitonobu Tomoike, Masafumi Kitakaze	45
18	A cardiac myosin light chain kinase regulates sarcomere assembly in the vertebrate heart 2007 ·Journal of Clinical Investigation ·Osamu Seguchi, Seiji Takashima, Satoru Yamazaki, Masanori Asakura, Yoshihiro Asano, Yasunori Shintani, Masakatsu Wakeno, Tetsuo Minamino, Hiroya Kondo, Hidehiko Furukawa, Kenji Nakamaru, Asuka Naito, Tomoko Takahashi, Toshiaki Ohtsuka, Koichi Kawakami, Tadashi Isomura, Soichiro Kitamura, Hitonobu Tomoike, Naoki Mochizuki, Masafumi Kitakaze	126
19	Development of Novel Simian Immunodeficiency Virus Vectors Carrying a Dual Gene Expression System 2000 ·Human Gene Therapy ·Toshihiro Nakajima, Kenji Nakamaru, Eiji Ido, Keiji Terao, Masanori Hayami, Mamoru Hasegawa	38
20	Selective Expression of β7 Integrin on Lymphocytes Undergoing Apoptosis in Lymphoid Tissues 1998 ·Biochemical and Biophysical Research Communications ·Hirofumi Akari, Hideo Yagita, (unknown), Kenji Nakamaru, (unknown), (unknown), Akio Adachi	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact